Posted on April 29, 2020 by Sitemaster
Alas … once again we hear that the combination of androgen receptor blockade (with enzalutamide/Xtandi) + a checkpoint inhibitor (the PD-L1 inhibitor atezolizumab/Tecentriq) has had no clinically meaningful impact on the overall survival (OS) of men with metastatic, castration-resistant prostate cancer (mCRPC) compared to enzalutamide alone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab, castration-resistant, checkpoint, enzalutamide, inhibitor, mCRPC, metastatic | Leave a comment »
Posted on March 29, 2019 by Sitemaster
We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …
Filed under: Uncategorized | Tagged: checkpoint, CTLA4, immunotherapy, inhibition, PD-1, PD-L1, risk | 1 Comment »
Posted on August 8, 2017 by Sitemaster
Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antibody, checkpoint, immune, inhibitor, outcome, test, trial | 4 Comments »
Posted on April 30, 2015 by Sitemaster
Alas, our friends at The Daily Telegraph in the UK seem to have managed to hyperinflate some early scientific findings into an overnight cure for prostate cancer in general and metastatic, castration-resistant prostate cancer in particular. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: B cell, checkpoint, inhibition, oxaliplatin, suppression | 8 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 